Benefits
Standardized Liposterolic Extract
Sabalselect® provides a quality-controlled, CO2-extracted saw palmetto standardized for fatty acids and sterols. Consistent manufacturing is a quality-control claim, not a health benefit; a well made extract still has to work in a trial, and this one has not.
Lower-Urinary-Tract Comfort (Cautious)
Saw palmetto is traditionally used to support normal urinary flow and comfort in aging men. Honest context: rigorous placebo-controlled trials have generally not shown benefit beyond placebo, so symptomatic use should be approached with realistic expectations. New or worsening urinary symptoms in older men need a medical assessment first, because infection, urinary retention and prostate cancer can produce the same complaints.
Hormone-Pathway Interest
Saw palmetto's fatty acids are reported to interact with the enzyme that converts testosterone to dihydrotestosterone in laboratory models. This is the proposed rationale for prostate support, though it has not translated into consistent clinical benefit.
Generally Well-Tolerated Option
For men who wish to try a botanical for prostate comfort, saw palmetto has a favorable tolerability profile. It is best viewed as a gentle traditional option rather than a substitute for evaluated medical therapy.
Mechanism of action
5-Alpha-Reductase Interaction
Saw palmetto liposterolic constituents are reported to inhibit 5-alpha-reductase, the enzyme converting testosterone to dihydrotestosterone (DHT) implicated in prostate growth — though in the human trials saw palmetto did not lower PSA compared with placebo, which suggests any effect on this pathway in the body is very small.
Anti-Inflammatory Activity
The extract may modulate inflammatory mediators and 5-lipoxygenase pathways in prostate tissue, a proposed contributor to symptom relief, supported mainly by laboratory data.
Alpha-Adrenergic and Receptor Effects
Saw palmetto has been reported to interact with adrenergic and other receptors involved in lower-urinary-tract smooth-muscle tone, though clinical relevance is uncertain given negative trial outcomes.
Clinical trials
Double-blind randomized trial of saw palmetto extract 160 mg twice daily versus placebo for one year in 225 men over age 49 with moderate-to-severe lower-urinary-tract symptoms.
225 men with moderate-to-severe BPH symptoms.
There was no significant difference between saw palmetto and placebo in symptom scores, urinary flow rate, prostate size, residual volume, quality of life, or PSA. The symptom score difference was 0.04 points on a scale where about three points is the usual threshold for a noticeable change, which is no difference at all.
Randomized trial escalating saw palmetto extract from 320 to 960 mg/day versus placebo over 72 weeks for lower-urinary-tract symptoms, with dose increases at 24 and 48 weeks.
369 men with lower-urinary-tract symptoms.
Increasing doses of saw palmetto did not reduce urinary symptoms more than placebo; the group mean difference was 0.79 points favoring placebo, and saw palmetto did not beat placebo on any secondary outcome either. Reinforces that higher doses do not rescue efficacy.
Cochrane systematic review of randomized trials of Serenoa repens for benign prostatic hyperplasia, including many placebo-controlled comparisons. Cochrane updated this review in 2023, covering 27 trials and 4,656 men, and reached the same conclusion: saw palmetto alone provides little to no benefit.
Pooled across thousands of men in randomized trials.
Saw palmetto was not more effective than placebo for urinary symptoms, urine flow or prostate size, and the review stated this held at double and triple doses as well. Supports the honest framing that the rigorous evidence base is largely null.